How the Chinese Society of Clinical Oncology is helping to turn China into a world-class destination for oncology research
Oncology research has become a hot topic for biopharma companies in China, in large part due to the growing epidemic of cancer resulting from increased tobacco use, unhealthy lifestyles, and the aging population. As I’ve noted in previous blogs, one-third of global lung cancer cases and approximately one-half of all diagnoses of gastric, liver, and esophageal cancer cases now occur in China, and improving outcomes for these patients has become a priority for the government and for the industry.
One organization that is driving the fight against cancer in China is the Chinese Society of Clinical Oncology (CSCO). CSCO is a professional group made up of...